These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 19282831)

  • 1. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis.
    Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL
    Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
    Pei XY; Dai Y; Grant S
    Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O
    Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
    Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
    Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.
    Shi W; Han X; Yao J; Yang J; Shi Y
    Leuk Res; 2012 Jun; 36(6):749-55. PubMed ID: 22475365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib.
    Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G
    Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.
    Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O
    Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species.
    Denlinger CE; Rundall BK; Jones DR
    J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species.
    Rahmani M; Reese E; Dai Y; Bauer C; Payne SG; Dent P; Spiegel S; Grant S
    Cancer Res; 2005 Mar; 65(6):2422-32. PubMed ID: 15781658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coadministration of the heat shock protein 90 antagonist 17-allylamino- 17-demethoxygeldanamycin with suberoylanilide hydroxamic acid or sodium butyrate synergistically induces apoptosis in human leukemia cells.
    Rahmani M; Yu C; Dai Y; Reese E; Ahmed W; Dent P; Grant S
    Cancer Res; 2003 Dec; 63(23):8420-7. PubMed ID: 14679005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
    Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
    Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
    Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
    Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically.
    Sato A; Asano T; Ito K; Sumitomo M; Asano T
    BJU Int; 2012 Apr; 109(8):1258-68. PubMed ID: 21895936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Synergistic effects of proteasome inhibitor and histone deacetylase inhibitor on apoptosis and aggresome formation in T lymphoma cells].
    Jiang XX; Zhang QL; Chen XY; Wu WL; Shen ZX; Zhao WL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1215-9. PubMed ID: 19840453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells.
    Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S
    Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
    Sato A; Asano T; Ito K; Asano T
    J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
    Shi WY; Wang L; Xiao D; Yao Y; Yang F; Jiang XX; Leboeuf C; Janin A; Chen SJ; Zhao WL
    Ann Hematol; 2011 Jan; 90(1):53-8. PubMed ID: 20617436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic effect of bortezomib and valproic acid treatment on the proliferation and apoptosis of acute myeloid leukemia and myelodysplastic syndrome cells.
    Wang AH; Wei L; Chen L; Zhao SQ; Wu WL; Shen ZX; Li JM
    Ann Hematol; 2011 Aug; 90(8):917-31. PubMed ID: 21340723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arsenic trioxide and proteasome inhibitor bortezomib synergistically induce apoptosis in leukemic cells: the role of protein kinase Cdelta.
    Yan H; Wang YC; Li D; Wang Y; Liu W; Wu YL; Chen GQ
    Leukemia; 2007 Jul; 21(7):1488-95. PubMed ID: 17495969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.